Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Figure 8

The meta-analysis results for total adverse events and severe adverse events in different dose groups after afatinib treatment in advanced NSCLC with EGFR mutation: (a) comparison of total adverse events in different dose groups and (b) comparison of severe adverse events in different dose groups.

(a)

(b)